Theratechnologies shares surge 25% amid $254m Future Pak takeover
Contract manufacturer Future Pak will acquire Theratechnologies in a $254m deal, bringing an end to a drawn-out sale process of …
Contract manufacturer Future Pak will acquire Theratechnologies in a $254m deal, bringing an end to a drawn-out sale process of …
The UK’s Labour Government has revealed its ’10-Year Health Plan’ for the country’s National Health Service (NHS). Speaking at a community …
BioVersys and Shionogi have entered a research and exclusive licence option agreement for the co-development of new ansamycin leads from …
Regeneron has won US Food and Drug Administration (FDA) approval for Lynozyfic (linvoseltamab-gcpt), marking the entry of another BCMAxCD3 bispecific …
Ligand Pharmaceuticals’ wholly owned subsidiary LNHC has concluded its merger with Channel Therapeutics’ CHRO Merger Sub, resulting in the formation …
Only 9% of life sciences professionals understand U.S. and EU artificial intelligence (AI) regulations well.[1] Let that sink in. While your executive …
As the focus on personalized, equitable healthcare continues to intensify, social determinants of health (SDoH) have attracted significant attention in …
Dizal has received US Food and Drug Administration (FDA) approval for Zegfrovy (sunvozertinib) to treat adults with locally advanced or …
Experts are emphasising that safeguarding patient data from corporations and cyberattacks is vital for the NHS to create a single …
Gilead’s recently approved drug for HIV prevention, Yeztugo (lenacapavir), has the potential to transform the pre-exposure prophylaxis (PrEP) sector in …
Sanofi has agreed to invest up to $25m in Adagene, which will enable the latter to fund its research and …
US President Donald Trump’s One Big Beautiful Bill Act (H.R. 1) has narrowly passed after US Vice President JD Vance …
Vertex Pharmaceuticals has won approval in Europe for its next-generation cystic fibrosis therapy Alyftrek (deutivacaftor/tezacaftor/vanzacaftor), shoring up the company’s dominance …
Merck KGaA has concluded the previously announced acquisition of SpringWorks Therapeutics for an enterprise value of €3bn ($3.4bn), after receiving …
Cell and gene therapies (CGT) offer hope to patients living with life-threatening conditions where limited treatment options may be available …